HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria
- 15 March 2020
- journal article
- research article
- Published by Elsevier BV in European Urology Focus
- Vol. 6 (2), 284-291
- https://doi.org/10.1016/j.euf.2018.09.016
Abstract
No abstract availableKeywords
Funding Information
- Shanghai Shen Kang Hospital Development Center (16CR2003A)
This publication has 21 references indexed in Scilit:
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- A Noninvasive Multianalyte Urine-Based Diagnostic Assay for Urothelial Cancer of the Bladder in the Evaluation of HematuriaMayo Clinic Proceedings, 2012
- Genome-wide Analysis of CpG Island Methylation in Bladder Cancer Identified TBX2, TBX3, GATA2, and ZIC4 as pTa-Specific Prognostic MarkersEuropean Urology, 2012
- Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urineBMC Medical Genomics, 2011
- Cancer epigenetics reaches mainstream oncologyNature Medicine, 2011
- Epigenetics in CancerNew England Journal of Medicine, 2008
- Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiologyUrology, 2001
- Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-upUrology, 2001
- A PROSPECTIVE ANALYSIS OF 1,930 PATIENTS WITH HEMATURIA TO EVALUATE CURRENT DIAGNOSTIC PRACTICEJournal of Urology, 2000